DELSA/GOV 3rd Health meeting - Valérie PARIS


Published on

This presentation by Valérie PARIS was made at the 3rd Joint DELSA/GOV Health Meeting, Paris 24-25 April 2014. Find out more at

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

DELSA/GOV 3rd Health meeting - Valérie PARIS

  1. 1. USER FEES AND COST-SHARING IN OECD COUNTRIES 3rd Annual Meeting of the Joint Network on Fiscal Sustainability of Health Systems Paris, OECD, 25 April 2014
  2. 2. Organisation of health care coverage Main source of basic health care coverage Countries Tax-funded health system Australia, Canada, Denmark, Finland, Iceland, Ireland, Italy, New Zealand, Norway, Portugal, Spain, Sweden, United Kingdom Health insurance system Single payer Greece, Korea, Luxembourg, Poland, Slovenia, Turkey, Hungary Multiple insurers, with automatic affiliation Austria, Belgium, France, Japan Multiple insurers, with choice of insurer Chile, Czech Republic, Germany, Israel, Mexico, the Netherlands, Slovak Republic, Switzerland, United States
  3. 3. Section 4. Comprehensiveness of basic health care coverage Section 4 aims to assess the level of basic health care coverage to which “typical” working-age adults are entitled to. Responses should not consider children, seniors and other categories of population which may be entitled to higher levels of benefits (e.g. people with serious illnesses). In countries with multiple insurers allowed to offer different levels of benefits, responses should refer to the most frequent or most typical situation. Question 13. Is there a general deductible* that must be met before basic health coverage pays a share of the cost or the full cost of covered services? □ Yes If so, what is the amount of the deductible that must be met before basic primary health coverage pays/reimburses? (national currency units) ______ What is the period in which the deductible applies (e.g. year, lifetime, episode of illness, etc.)? □ No Information collected in the Health Systems Characteristics survey
  4. 4. Information collected in the Health Systems Characteristics survey Outpatient primary care physician* contacts Examples: - Free at the point of care; - Copayment of €2 per visit; - Copayment of €10 for the first of each semester; - Co-insurance of 20%; - Not reimbursed if not referred Pharmaceuticals Examples: - Copayment per prescription item ($5 for generics and $20-25 for brandname drugs); - Cost-sharing: 10% of cost with a min of €5 and a max of 10€ per item; - Cost-sharing of 0%, 35%, 65% or 85% depending on drug category + €0.50 per item - Deductible of SEK 900 beyond which cost-sharing diminishes by step as spending increases (from 50%, 25%, 10% and 0%). - Any difference between actual price and reference price for medicines subject to reference price Question 14. Are patients required to share the costs of health care for the services and goods listed below? Please indicate the type and level of cost-sharing left at the charge of users by basic primary health coverage, in the case of an adult with no specific exemption of user charge. If there is no cost-sharing, please indicate "no cost-sharing".
  5. 5. Different types of cost-sharing Co-insurance: cost-sharing requirement whereby the insured person pays a share of the cost of the medical service (e.g. 10%). Copayment: fixed sum (e.g. USD 15) paid by an insured individual for the consumption of itemized health care services (e.g. per hospital day, per prescription item). User fee, prescription fee sometimes used as synonymous. Deductible: lump sum threshold below which an insured person must pay out-of-pocket for health care before insurance coverage begins. It is defined for a specific period of time: one year, one quarter or one month. Deductibles can apply to a specific category of care (e.g. physicians’ visits, pharmaceutical spending) or to all health expenditures (general deductible). Extra-billing: refers to any difference between the price charged and the price used as a basis for reimbursement purpose. In the pharmaceutical sector, where “reference prices” are often used, a fixed reimbursement amount is determined for a cluster of products, while sellers remain free to set a higher price. The patient pays out-of-pocket any difference between the price of a medicine and the reference price.
  6. 6. Out-of-pocket payments (System of health account) Spending by people without health coverage Cost-sharing for health care goods and services which are partially covered Cost-sharing and user charges left by basic health coverage (potentially covered by PHI in some countries) + Potential extra-billing Payment for goods and services which are not covered Informal payments User fees and cost-sharing: what are we talking about?
  7. 7. From « entitlements » to actual coverage Entitlements: Who is covered? for what (benefit basket)? At what level? (with or without cost-sharing) Health spending level and financing structure Availability of health care supply Affordability of health care services and goods Cost- sharing exemptions and caps
  8. 8. • Canada and Hungary indicated that patients can access primary care services for free. • Japan indicated a 30% co-insurance rate for these services. • The share of PHI and OOP payments in spending for basic medical and diagnostic care is: Examples 0% 10% 20% 30% 40% 50% Canada Hungary Japan OOP PHI
  9. 9. User charges: where are we? Cost-sharing on outpatient medical care Primary care Specialised care Free of charge for all Canada, Denmark, Hungary, Italy, Poland, United Kingdom Canada, Denmark, Hungary, New Zealand, Poland, Spain, United Kingdom Free of charge for some Australia (≈80% of GP services) Chile (public-public) Germany (SHI-85% pop) Greece (public provider) Ireland (40% of pop) Mexico (public-public) Australia, Germany (SHI) Greece (public providers), Ireland (public-public) Mexico (public-public) Deductible Austria (specific) Netherlands (general) Austria, Israel (specific) Netherlands (general) Copayment Belgium, Czech Republic, Finland, Iceland, Israel Belgium, Czech Republic, Finland, Italy, Portugal Co-insurance Chile (provider choice) Japan, Korea, Luxembourg Chile, Japan, Korea, Luxembourg, Slovenia Copayment+co-insurance France France, Iceland Deductible + co-insurance Switzerland Switzerland Full price Ireland (60% of pop)
  10. 10. • Inpatient care is more often free of charge or only subject to small daily copayments, except in a few countries with co-insurance rates (France, Japan, Korea, etc) • In a few countries, inpatient care is free for patients admitted as public patients in public hospital but subject to copayments for patients admitted as private patients (Australia, Italy) • User charges are the common rule for pharmaceuticals, with a few exceptions. They most often take the form of co-insurance (with differentiated rates) or fixed prescription charges. Several countries also have deductibles User charges: where are we?
  11. 11. Chronically ill and/or disabled Low-income Entitled to social benefits Seniors Children Pregnant women Beyond an absolute cap on cost-sharing Beyond a cap related to income Australia       Austria     Belgium       Canada Chile      Czech Republic     Denmark     Finland      France     Germany    Greece      Hungary   Iceland     Ireland      Israel      Italy      Japan     Korea     Luxembourg      Mexico  Netherlands   New Zealand    Norway     Poland  Portugal     Slovak Republic  Slovenia     Spain   Sweden    Switzerland    United Kingdom     Reductions or exemptions of copayments for specific population
  12. 12. Note: Source: OECD Health Statistics 2013 What do patients pay for? Shares of out-of-pocket medical spending by services and goods, 2011 (or nearest year)
  13. 13. • They can potentially increase revenues to finance health care • They can potentially reduce excessive demand for health care (moral hazard), i.e. reduce spending related to this fraction of demand Arguments in favour of cost-sharing
  14. 14. • More than 130 studies on the impact of copayments on pharmaceutical consumption: – They reduce the consumption of non-essential but also essential medicines – The impact on health is not well evaluated… but what are « essential medicines » if we can live without them without any impact on health? – Short term impact on spending • Studies on other types of care (physicians visits, emergency, etc) – Reduction in utilisation in some cases, sometimes only temporary – Substitutions with other types of care is not well known – The impact on total spending in not well known Arguments against copayments: impact on demand, spending and health
  15. 15. • Copayments target patients while more than 4/5 of spending is generated by physicians’ prescriptions. Do we think patients are better placed to make clinical decisions? Do we want these decisions to be influenced by ability to pay? • Copayments are inequitable – “Tax on the ill seeking care” – They disproportionally affect low-income population • Copayments generate administration costs • Copayments are politically difficult to introduce, relatively easy to increase • Copayments are limited in their capacity to raise resources because of concentration of spending Arguments against copayments
  16. 16. • Make sure they are based on value and provide appropriate incentives – Incentives to use cheaper alternatives where available ( Reference prices for medicines, Differentiated copayments) – Remove copayments from cost-effective treatments you want people to take and comply with – Use them to encourage virtuous patient’s pathways, use of medical records (France, Belgium) – Present lower copayments as a bonus rather than higher copayments as a penalty • Protect low-income groups against copayments • Do not neglect alternative measures such as HTA-based updating of the benefit package, promotion of self-care (including access to OTC medicines). If you really want to keep or introduce cost-sharing